StockData
FibroBiologics, Inc. logo

FibroBiologics, Inc. (FBLG) stock

FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 2/30
$0.84−0.06 (-6.72%)

Close on Nov 18, 2026Market cap $5.59MP/E –Yield –

FibroBiologics net income

Net income is the profit left for shareholders after every expense, interest and tax.

FibroBiologics's net income for the twelve months ending Jun 30, 2026 was -$18.14M. For fiscal 2025 it was -$18.65M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.65M–
FY2024Dec 31, 2024-$11.16M–
FY2023Dec 31, 2023-$16.49M–
FY2022Dec 31, 2022-$5.12M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.12M–
Q1 FY2026Mar 31, 2026-$5.00M–
Q4 FY2025Dec 31, 2025-$3.24M–
Q3 FY2025Sep 30, 2025-$5.78M–
Q2 FY2025Jun 30, 2025-$4.66M-618.7%
Q1 FY2025Mar 31, 2025-$4.97M–
Q4 FY2024Dec 31, 2024-$3.10M–
Q3 FY2024Sep 30, 2024-$500.00K–
Q2 FY2024Jun 30, 2024$898.00K–
Q1 FY2024Mar 31, 2024-$8.46M–
Q4 FY2023Dec 31, 2023-$9.72M–
Q3 FY2023Sep 30, 2023-$2.19M–
Q2 FY2023Jun 30, 2023-$2.16M–
Q1 FY2023Mar 31, 2023-$2.42M–

More FibroBiologics figures

See a number that looks wrong?